Ensysce Biosciences' Newly Formulated Oxycodone Product Shows Resistance To Tampering, Abuse

Ensysce Biosciences Inc ENSC announced topline results from a human abuse potential (HAP) study for PF614.
PF614 is a new class of analgesia, a Trypsin Activated Abuse-Protected (TAAP) oxycodone product.
The HAP study was designed to test if known recreational drug users "liked" the product and is critical for new drugs in this class.
The primary measure in this study, "drug liking," is known to correlate with a drug's potential for abuse.
In the study, PF614 powder produced significantly lower peak "drug liking" when compared with intranasal crushed IR oxycodone.
Furthermore, in the first-period analysis of initial impressions of each drug, a similarly strong difference was noted between PF614 (n=8) and crushed IR oxycodone (n=10), even with this smaller cohort of subjects.
Related: Ensysce Biosciences, Quotient Partner To Work On Novel Opioid To Prevent Abuse and Overdose.
Statistically significant differences in peak effects (Emax) between PF614 and crushed IR oxycodone intranasal were also demonstrated for the secondary endpoint of "take drug again," where PF614 produced only 27% as high an Emax score as crushed oxycodone among recreational drug users.
Price Action: ENSC shares are up 11.10% at $3.45 session on the last check Monday.